Sign in

CIK 0001512762

  • Accelerated filer
  • Smaller reporting company

Coherus Oncology, Inc.

Sign in to watch
Ticker
CHRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
273615821
Phone
+1 650-649-3530
Business address
C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
Former names
Coherus BioSciences, Inc., BioGenerics, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Shares withheld for taxes President & CEO gave up 21,516 shares (to pay taxes)
  6. 4 Shares withheld for taxes Chief Scientific Officer gave up 3,477 shares (to pay taxes)
  7. 4 Shares withheld for taxes Chief Financial Officer gave up 7,077 shares (to pay taxes)
  8. 4 Shares withheld for taxes Chief Operating Officer gave up 7,146 shares (to pay taxes)
  9. 4 Exercise or conversion Director acquired 69,994 shares (option exercise)
  10. 3 Insider Initial Statement of Ownership
  11. 4 Open-market sale Chief Operating Officer sold 2,500 shares at $18.69 ($46,725)
  12. 4 Open-market sale President & CEO sold 12,500 shares at $18.56 ($231,960)
  13. 4 Open-market sale President & CEO sold 825,000 shares at $18.00 ($14,850,000)
  14. 4 Open-market sale Chief Financial Officer sold 3,159 shares at $19.59 ($61,872)
  15. 4 Open-market sale Chief Financial Officer sold 3,112 shares at $18.88 ($58,757)
  16. 4 Open-market sale Chief Operating Officer sold 2,500 shares at $19.26 ($48,150)
  17. 4 Open-market sale Chief Financial Officer sold 1,388 shares at $19.02 ($26,400)
  18. 4 Open-market sale Chief Financial Officer sold 3,159 shares at $19.00 ($60,021)
  19. 4 Open-market sale Chief Operating Officer sold 2,500 shares at $18.40 ($46,000)
  20. 4 Open-market sale Chief Financial Officer sold 740 shares at $21.78 ($16,117)

Page 10 of 20 · 399 filings